Paul McQuade of Greenberg Traurig, LLP shares some legal aspects of federal technology investment and their potential impact on intended markets. View Slide Deck
Dr. Todd Haim of the National Cancer Institute SBIR Development Center describes the NCI’s SBIR and STTR programs, their structure, the Institute’s funding interests, and FAQs. View Slide Deck
Dr. Meg Mooney of the National Cancer Institute discusses new initiatives to accelerate development of cancer therapies in the era of precision medicine. View Slide Deck
Mr. Henry Ahn of the National Science Foundation speaks on the NSF’s SBIR and STTR programs. View Slide Deck
Amber Dance Nature 540, 471–473 (15 December 2016) doi:10.1038/nj7633-471a Published online 14 December 2016 This article was originally published in the journal Nature Nervous about your grant application’s chance of success? Get help to make every word count. Read article online Jiri Lukas’ research centre was at a crossroads four years ago. Bankrolled by the Novo Nordisk Foundation, […]
SBIR/STTR awards account for over $780,000,000 awarded per year by NIH alone. These are excellent sources of funding aimed at promoting R&D activities of US-based small businesses as well as collaborations with Academics. SBIR/STTRs differ from traditional NIH mechanisms in that they are highly product driven and ultimately are seeking commercialization of novel therapies, diagnostics, […]
A tough and ever-changing question. Perhaps a quick personal historical overview might help shed light on the statement above. When I started out in this field in many years ago, there was a “three strike” policy. That basically meant that you could submit an original proposal, and then two revisions. If you didn’t get the […]
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) supports research on many of the most common, costly, and chronic conditions to improve health. With a FY2016 budget of over $1.8 Billion, the NIDDK supports R&D from basic research and early discovery stage projects all the way through late stage clinical trials. The […]